CLLS CLLS
Company Profile ↓Company Overview
CLLS (CLLS) is a publicly traded company listed on with a market capitalization of $279.95M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 56.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $72.95M (+75.8% YoY); net profit $-67.59M.
- Trailing 12 Months Year-on-year growth — revenue +75.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 56.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 56.12% |
| 1 Year: | 75.76% |
Stock Price Performance
| 1 Year: | -7.62% |
| 6 Months: | -20.96% |
| 3 Months: | -25.80% |
| 1 Month: | -13.35% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 56.1% over 5 years.
CONS
- Trading 47.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 10.65M | 16.73M | 35.17M | 10.40M | 5.78M |
| Cost of Revenue | - | 2.02M | 2.42M | 2.36M | 3.00M | 2.32M |
| Gross Profit | - | 8.64M | 14.30M | 32.81M | 7.40M | 3.46M |
| Operating Expenses | - | 22.82M | 23.89M | 24.77M | 24.75M | 28.62M |
| Operating Income | - | -14.18M | -9.59M | 8.04M | -17.35M | -25.17M |
| EBITDA | - | -11.29M | -16.66M | 7.71M | -19.61M | -11.26M |
| Interest Expense | - | 1.91M | 2.06M | 2.11M | 2.03M | 1.93M |
| Pretax Income | - | -18.13M | -23.74M | 589.00K | -26.74M | -17.72M |
| Tax Provision | - | 0 | 0 | 0 | -423.00K | 46.00K |
| Net Income | - | -18.13M | -23.73M | 589.00K | -26.32M | -17.77M |
| Diluted EPS | - | -0.18 | - | 0.01 | -0.26 | -0.18 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 19.17M | 755.00K | 41.51M | 72.95M |
| Cost of Revenue | - | 8.48M | 7.42M | 9.18M | 9.80M |
| Gross Profit | - | 10.69M | -6.66M | 32.32M | 63.15M |
| Operating Expenses | - | 100.35M | 90.64M | 91.88M | 96.23M |
| Operating Income | - | -89.67M | -97.30M | -59.55M | -33.08M |
| EBITDA | - | -76.38M | -92.64M | -9.46M | -39.85M |
| Interest Expense | - | 3.79M | 5.31M | 7.45M | 8.11M |
| Pretax Income | - | -98.60M | -116.47M | -36.76M | -68.02M |
| Tax Provision | - | 87.00K | 371.00K | 0 | -423.00K |
| Net Income | - | -106.14M | -101.06M | -36.76M | -67.59M |
| Diluted EPS | - | -2.33 | -1.77 | -0.41 | -0.67 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 261.22M | 334.27M | 383.54M | 324.72M |
| Current Assets | - | 143.81M | 233.01M | 287.07M | 236.25M |
| Cash & Equivalents | - | 89.79M | 136.71M | 143.25M | 61.53M |
| Inventory | 0 | 0 | - | - | - |
| Receivables | - | 772.00K | 569.00K | 6.71M | 14.40M |
| Total Liabilities | - | 135.28M | 249.57M | 252.51M | 248.82M |
| Current Liabilities | - | 62.99M | 155.14M | 166.27M | 145.75M |
| Long Term Debt | - | 13.57M | 28.44M | 43.99M | 51.22M |
| Total Debt | - | 75.77M | 85.06M | 91.46M | 90.73M |
| Total Equity | - | 117.97M | 84.69M | 131.03M | 75.90M |
| Shares Outstanding | - | 45.68M | 71.75M | 72.09M | 100.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -87.44M | -24.75M | 22.99M | -39.40M |
| Investing Cash Flow | - | -2.76M | -15.51M | -102.81M | -29.48M |
| Financing Cash Flow | - | 1.15M | 82.86M | 89.11M | -16.76M |
| Capital Expenditure | - | -2.44M | -1.07M | -3.84M | -3.53M |
| Free Cash Flow | - | -89.89M | -25.82M | 19.15M | -42.93M |
| Net Change in Cash | - | -89.06M | 42.61M | 9.29M | -85.65M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 55.7% | -882.6% | 77.9% | 86.6% |
| Operating Margin % | - | -467.7% | -12,887.8% | -143.5% | -45.3% |
| Net Margin % | - | -553.6% | -13,385.3% | -88.6% | -92.7% |
| ROE % | - | -90.0% | -119.3% | -28.1% | -89.1% |
| ROCE % | - | -45.2% | -54.3% | -27.4% | -18.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLLS
Cellectis Q2 Results Set for Aug. 6; No Call Planned - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUk1Gc2NHd3lOU1JLcUd5RG5ISUpxcl9Vd292T04zbjJubkllbzhjYUJBc1NNMlhmdEtUczB6cGdSZFhHZXVjMDZidTZkbzhpd1NmbDJacHREY1EwcmpmY0xVbjhaNnhWNDRnT1kzcnUtN3gzN2s1VVFRRUVjS1ZBTzlOM2pnVDhUQ0tIdk…
CLLS Stock Rallies Over 24% After Hours — Here's Why - Stocktwits
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNNmV0dXZobDAtNGJ0bmdDdHRybnhseTM3NHQ0cWhoYW93MEtOUGFZTmZ1cy02QXZ6ZXlwazZVbkJZb2hXYmFrQTdaaWd5UzczZHhiZ29wWVZsV0xJeWNWdmxEWGFzYmxTdzBPc0ZSS2JYZjNNcXJSeXdvc05RWGd6ZFJ0RGpvUjJLemdBSD…
Cellectis (CLLS) to Post Quarterly Earnings on Thursday - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQZVZScFJQc2V3aDZ3Wk5vMnZKSFNnZ01MOTVHUXF6bkktV2huZ1hCR1liRXFBVDB5QVhmRFZxSl9VdTFQX09xVHdkVFhwbXpzeWp3SE1wbWFRZVZiajYxTGtRN1Q1bWV0XzgzYVdGRXhyRXRyYUVvRktCOVlwc0pxcW0tOFdDbU1tbEVVbG…
CLLS|Cellectis SA|Price:2.920|Chg%:+0.170 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE5ITUNzeXRCWWxkXzJ1Q1pJd1FkWGR2Y0RTRkkxWFM1bDJsaTB6Sm9PMTFZTUVSSnpaemtrUXkzV1Fzd1F4Y2owV1F4cVpSc3ZYb2NXbi1Udy10LWF6TmdjSTcwVEd3dV8xbWFDYXNn?oc=5" target="_blank">CLLS|Cellectis SA|P…
ETFs Investing in Cellectis S.A. Sponsored ADR Stocks - TradingView
<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTFBMc3pXNC1Na29xSmxoblhrZUVXQ2VhS1J5ZzdocjFJcU9lNXNBMDZIVEs0WTVDSURmZFoxeWQzd3ctankxWVVaNEptbFB6RkxidUxEeTRhTUpFLXJDM1NVQWZwUQ?oc=5" target="_blank">ETFs Investing in Cellectis S.A. …
Biggest stock movers Wednesday: CBRL, CLLS, SMCI, trucking stocks, and more (SMCI:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNa3V5YURYTDk4RzRmak1hRE5XTzhOQkZlekt5WTB1T2xDLUhQSTBsVXJVMEd5c1YxS21qNDgxMldpeDlhbWpkTFRlemlTVXNySmNUYUMtWFJGZnBQQURKZWJHVVNaVG02dngxR3l0YThfcU9VWFAyeXgxUGE1SVJfT2swbkRUbVBWQW90cV…
CLLS — Frequently Asked Questions
What is the current share price of CLLS?
As of 2026-08-05 17:25 PDT, CLLS trades at $2.79 on NASDAQ/NYSE. Its 52-week range is $2.53 to $5.35.
What is the market capitalisation of CLLS?
CLLS has a market capitalisation of $279.95M on NASDAQ/NYSE.
What is the P/E ratio of CLLS?
CLLS trades at a trailing price-to-earnings (P/E) ratio of -4.16. Its price-to-book (P/B) ratio is 3.69.
What is the return on equity (ROE) of CLLS?
CLLS has a return on equity (ROE) of -89.05%. Its return on capital employed (ROCE) is -18.48%.
Is CLLS a good stock to buy?
This page provides a data-driven analysis of CLLS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.